Germany’s Merck KGaA on Thursday issued a more ambitious medium-term growth forecast for its Life Science unit, a supplier of materials and lab gear for the biotech industry.
Life Science division revenues are now expected to grow 7% to 10% per year, excluding the effect of currencies and acquisitions, significantly above market growth and up from a previous goal of 6% to 9%, the diversified company said.
In a statement on its capital markets day on Thursday, the family-controlled group added that it expects group sales to grow organically by more than 6% per year on average through 2025, driven by demand for the Life Science unit’s bioprocessing products, new pharmaceuticals and semiconductor chemicals.
https://kelo.com/2021/09/09/merck-kgaa-lifts-growth-forecast-for-life-science-tools-business/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.